Visual Analysis of Bone Malignancies Immunotherapy: A Bibliometric Analysis From 2010 to 2023

Authors

Kaiyu Shen
Liu Yang
Shuaiyi Ke
Wencang Gao

Publication Date

3-29-2024

Journal

Medicine

Abstract

Background: Bone malignancies (BM), including osteosarcoma, Ewing's sarcoma, chondrosarcoma, and chordoma, are characterized by high rates of recurrence and mortality, despite the availability of diverse treatment approaches. Immunotherapy has gained increasing importance in cancer treatment. However, there is a lack of comprehensive studies that utilize bibliometric analysis to explore immunotherapy for BM.

Methods: A literature search of English studies on BM and immunotherapy from 2010 to 2023 was conducted in the Web of Science Core Collection database. Bibliometric analysis tools such as VOSviewer, CiteSpace, and R Studio were utilized to examine global trends and research hotspots in this field.

Results: A total of 719 eligible articles, including 528 original research articles and 191 reviews, were analyzed. The number of publications has shown an increasing trend over the past 14 years, particularly in the last 5 years. The majority of the published articles on this topic originated from China (284 articles), followed by the United States and Japan. The institution with the highest number of publications and citations was the University of Texas MD Anderson Cancer Center (30 articles; 1638 citations). Dean A. Lee (12 articles) and Richard Gorlick (576 citations) were the authors with the highest contribution in terms of article count and citation count, respectively. Among these journals, Frontiers in Oncology had the highest number of articles (39 articles), while the Journal of Clinical Oncology had the highest number of citations (1878 citations). Additionally, there has been a shift in the keywords from "antitumor activity" and "NK cells" to popular topics such as "PD-L1," "open label," and "single arm."

Conclusion: A better understanding of the current status and prospects of immunotherapy for BM is crucial for the rationale selection of appropriate BM patients for immunotherapy. This study is expected to help clinical physicians and researchers gain comprehensive insights into the developmental trends of BM immunotherapy, providing practical guidance for the application of immunotherapy in BM patients.

Keywords

Humans, Immunotherapy, Bone Neoplasms, Osteosarcoma, Sarcoma, Ewing, Bibliometrics, bibliometric study, bone malignancies, clinical trials, immunotherapy, VOSviewer

DOI

10.1097/MD.0000000000037269

PMID

38552042

PMCID

PMC10977522

PubMedCentral® Posted Date

3-29-2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes